323 related articles for article (PubMed ID: 31098654)
1. An increase in plasma brain derived neurotrophic factor levels is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: secondary outcome analysis of the OFFER randomized clinical trial.
Pawełczyk T; Grancow-Grabka M; Trafalska E; Szemraj J; Żurner N; Pawełczyk A
Psychopharmacology (Berl); 2019 Sep; 236(9):2811-2822. PubMed ID: 31098654
[TBL] [Abstract][Full Text] [Related]
2. Telomerase level increase is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: Secondary outcome analysis of the OFFER randomized clinical trial.
Pawełczyk T; Grancow-Grabka M; Trafalska E; Szemraj J; Żurner N; Pawełczyk A
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Apr; 83():142-148. PubMed ID: 29241838
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia.
Pawełczyk T; Grancow-Grabka M; Kotlicka-Antczak M; Trafalska E; Pawełczyk A
J Psychiatr Res; 2016 Feb; 73():34-44. PubMed ID: 26679763
[TBL] [Abstract][Full Text] [Related]
4. Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods.
Pawełczyk T; Grancow M; Kotlicka-Antczak M; Trafalska E; Gębski P; Szemraj J; Żurner N; Pawełczyk A
BMC Psychiatry; 2015 May; 15():97. PubMed ID: 25934131
[TBL] [Abstract][Full Text] [Related]
5. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia.
Bentsen H; Osnes K; Refsum H; Solberg DK; Bøhmer T
Transl Psychiatry; 2013 Dec; 3(12):e335. PubMed ID: 24346133
[TBL] [Abstract][Full Text] [Related]
6. Omega-3 fatty acids reduce cardiometabolic risk in first-episode schizophrenia patients treated with antipsychotics: Findings from the OFFER randomized controlled study.
Pawełczyk T; Grancow-Grabka M; Żurner N; Pawełczyk A
Schizophr Res; 2021 Apr; 230():61-68. PubMed ID: 33684737
[TBL] [Abstract][Full Text] [Related]
7. BDNF serum levels in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study).
Strzelecki D; Kałużyńska O; Wysokiński A
Psychiatry Res; 2016 Aug; 242():54-60. PubMed ID: 27262086
[TBL] [Abstract][Full Text] [Related]
8. Serum brain-derived neurotrophic factors in Taiwanese patients with drug-naïve first-episode schizophrenia: Effects of antipsychotics.
Chiou YJ; Huang TL
World J Biol Psychiatry; 2017 Aug; 18(5):382-391. PubMed ID: 27643618
[TBL] [Abstract][Full Text] [Related]
9. Oxidative stress reduction related to the efficacy of n-3 polyunsaturated fatty acids in first episode schizophrenia: Secondary outcome analysis of the OFFER randomized trial.
Pawełczyk T; Grancow-Grabka M; Trafalska E; Szemraj J; Pawełczyk A
Prostaglandins Leukot Essent Fatty Acids; 2017 Jun; 121():7-13. PubMed ID: 28651701
[TBL] [Abstract][Full Text] [Related]
10. Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study.
Zhang Y; Fang X; Fan W; Tang W; Cai J; Song L; Zhang C
Psychopharmacology (Berl); 2018 Apr; 235(4):1191-1198. PubMed ID: 29392373
[TBL] [Abstract][Full Text] [Related]
11. Omega-3 fatty acid supplementation may prevent loss of gray matter thickness in the left parieto-occipital cortex in first episode schizophrenia: A secondary outcome analysis of the OFFER randomized controlled study.
Pawełczyk T; Piątkowska-Janko E; Bogorodzki P; Gębski P; Grancow-Grabka M; Trafalska E; Żurner N; Pawełczyk A
Schizophr Res; 2018 May; 195():168-175. PubMed ID: 29079060
[TBL] [Abstract][Full Text] [Related]
12. Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy.
Hori H; Yoshimura R; Katsuki A; Atake K; Igata R; Konishi Y; Nakamura J
World J Biol Psychiatry; 2017 Aug; 18(5):401-408. PubMed ID: 27409727
[TBL] [Abstract][Full Text] [Related]
13. Omega-3 polyunsaturated fatty acids (n-3 PUFAs), somatic and fatigue symptoms in cardiovascular diseases comorbid major depressive disorder (MDD): A randomized controlled trial.
Chang JP; Chang SS; Chen HT; Chien YC; Yang HT; Huang SY; Tseng PT; Chang CH; Galecki P; Su KP
Brain Behav Immun; 2023 Aug; 112():125-131. PubMed ID: 37301235
[TBL] [Abstract][Full Text] [Related]
14. Serum pro-BDNF/BDNF as a treatment biomarker for response to docosahexaenoic acid in traumatized people vulnerable to developing psychological distress: a randomized controlled trial.
Matsuoka Y; Nishi D; Tanima Y; Itakura M; Kojima M; Hamazaki K; Noguchi H; Hamazaki T
Transl Psychiatry; 2015 Jul; 5(7):e596. PubMed ID: 26151924
[TBL] [Abstract][Full Text] [Related]
15. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
[TBL] [Abstract][Full Text] [Related]
16. Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study.
Kudlek Mikulic S; Mihaljevic-Peles A; Sagud M; Bajs Janovic M; Ganoci L; Grubisin J; Kuzman Rojnic M; Vuksan Cusa B; Bradaš Z; Božina N
Nord J Psychiatry; 2017 Oct; 71(7):513-520. PubMed ID: 28671000
[TBL] [Abstract][Full Text] [Related]
17. Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes.
Chen DC; Wang J; Wang B; Yang SC; Zhang CX; Zheng YL; Li YL; Wang N; Yang KB; Xiu MH; Kosten TR; Zhang XY
Psychopharmacology (Berl); 2009 Dec; 207(3):375-80. PubMed ID: 19787338
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients.
Miodownik C; Maayan R; Ratner Y; Lerner V; Pintov L; Mar M; Weizman A; Ritsner MS
Clin Neuropharmacol; 2011; 34(4):155-60. PubMed ID: 21617527
[TBL] [Abstract][Full Text] [Related]
19. Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment.
Lee BH; Kim YK
Neuropsychobiology; 2009; 59(1):51-8. PubMed ID: 19270464
[TBL] [Abstract][Full Text] [Related]
20. Zinc monotherapy increases serum brain-derived neurotrophic factor (BDNF) levels and decreases depressive symptoms in overweight or obese subjects: a double-blind, randomized, placebo-controlled trial.
Solati Z; Jazayeri S; Tehrani-Doost M; Mahmoodianfard S; Gohari MR
Nutr Neurosci; 2015 May; 18(4):162-8. PubMed ID: 24621065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
